期刊文献+

FLAG方案治疗儿童难治性及复发急性髓细胞白血病8例疗效探讨 被引量:4

原文传递
导出
摘要 目的评价应用FLAG方案治疗儿童难治及复发急性髓细胞白血病的疗效及毒性反应。方法 2004年4月至2011年6月,共8例难治及复发急性髓细胞白血病患儿在中山大学孙逸仙纪念医院儿科接受了FLAG方案治疗,对患儿的临床资料进行回顾性分析。结果 1个疗程后,完全缓解率为75%(6/8),部分缓解率为25%(2/8),总有效率为100%。5例难治患儿中,3例达完全缓解,CR率60%,3例复发患儿均达完全缓解。该方案的主要毒副反应是感染、骨髓抑制和胃肠道反应。结论 FLAG方案是治疗儿童难治及复发急性髓细胞白血病一个选择,可为造血干细胞移植提供机会。
出处 《中国实用儿科杂志》 CSCD 北大核心 2012年第2期139-141,共3页 Chinese Journal of Practical Pediatrics
  • 相关文献

参考文献12

  • 1Kell J. Treatment of relapsed acute myeloid leukaemia [J]. Rev Recent Clin Trials, 2006,1 : 103-11.
  • 2吕善根.儿童难治性急性白血病的诊断和治疗[J].中国实用儿科杂志,2002,17(6):325-326. 被引量:9
  • 3顾龙君.儿童急性髓细胞白血病诊疗建议[J].中华儿科杂志,2006,44(11):877-878. 被引量:157
  • 4方建培,陈纯,金润铭,儿童白细胞的诊断和治疗[M].北京:人民卫生出版社,2008:182-183.
  • 5Gandhi V, Estey E, Keating M J, et al. Fludarahine potentiates metabolism of cytarabine in patients with acute myelogenous leu- kemia during therapy[J]. J Clin Oncol, 1993,11 : 116-124.
  • 6Jackson G, Taylor P, Smith GM, et al. A multicentre, open, non-comparative phase 1I study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating fac- tor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation [J]. Br J Haematol,2001,112:127-37.
  • 7Carella AM, Cascavilla N, Greco MM, et al. Treatment of "poor risk" acute myeloid leukemia with tludarabine, cytarabine and G-CSF (flag regimen) :a single center study [J ]. Leuk Lymph0- ma, 2001,40 : 295-303.
  • 8Tavil B, Aytac S, Balci YI, et al.Fludarabine, cytarabine, granu- locyte colony-stimulating factor, and idarubicin (flag-ida) for the treatment of children with poor-prognosis acute leukemia: the hacettepe experience [J]. Pediatr Hematol Oncol, 2010, 27: 517-528.
  • 9Mehta DR, Foou KA, Redner RL, et al.Fludarabine and cytara- bine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy [J]. Leukemia Res, 2011 ; 35 : 885-888.
  • 10Lee SR, Yang DH, Ahn JS, et al. The clinical outcome of flag chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia[J]. J Korean Med Sci, 2009, 24 : 498-503.

二级参考文献18

  • 1吴晓雄,达万明,李红华,赵瑜,王全顺,王书红,朱海燕.FLAG方案治疗难治/复发急性髓细胞性白血病的疗效观察[J].中国实验血液学杂志,2005,13(3):394-396. 被引量:18
  • 2卞寿庚.难治性急性白血病,中国癌症研究基金会第三届全国难治性白血病学术研讨会[M].北京:白血病淋巴瘤杂志社,2001.22.
  • 3-.关于难治性白血病诊断标准的建议[J].白血病,1997,6(3):2-2.
  • 4-.关于难治性白血病诊断标准的意义(草案)[J].白血病,2000,9(1):63-63.
  • 5Lamanna N, Weiss M. Purine analogs in leukemia. Adv Pharmacol,2004, 51:107-125.
  • 6Milligan DW, Wheatley K, Burnett AK. Fludarabine, cytosine arabiuoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol, 2004,127:238-239.
  • 7Pastore D, Specchia G, Carluccio P, et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol, 2003, 82:231-235.
  • 8Hanel M, Friedrichsen K, Hanel A, et al. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia. Onkologie,2001, 24:356-360.
  • 9Russo D, Pricolo G, Michieli M, et al. Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia. Leuk Lymphoma, 2001,40:335-343.
  • 10Jackson G, Taylor P, Smith GM, et al. A multicentre, open, noncomparative phase Ⅱ study of a combination of fludarabine phosphate,cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol, 2001, 112:127-137.

共引文献195

同被引文献59

  • 1赵桂兰.去甲氧柔红霉素治疗难治性急性髓系白血病的疗效分析[J].内蒙古医学院学报,2005,27(5):36-37. 被引量:4
  • 2殷慧君,张乐萍,陆爱东,王志宏,商晓云,刘捷.4-去甲氧柔红霉素治疗小儿急性白血病[J].中华血液学杂志,1996,17(4):205-205. 被引量:6
  • 3李慧,陈映霞,秦叔逵,何泽明.肿瘤治疗相关性白血病2例报告[J].临床肿瘤学杂志,2006,11(7):559-560. 被引量:3
  • 4张之南.血液病诊断及疗效标准.第3版.天津科学技术出版社,2008,152-1911.
  • 5顾龙君,陈静,曹兰芳,等.用去甲氧柔红霉素联合方案治疗儿童急性淋巴细胞性白血病.中华血液学杂志,2005,16(1):368-369.
  • 6Luo S, Cai F, Jiang L, et al. Clinical study of Mito-FLAG regimen in treatment of relapsed acute myeloid leukemia [ J ]. Exp Ther Med, 2013, 5(3) : 982-986.
  • 7Kim H, Lee JH, Joo YD, et al. Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial [ J ]. Acta Haematol, 2014, 132(1): 87-96.
  • 8Koh Y, Kim I, Bae JY, et al. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8[J]. Jpn J Clin Oncol, 2010, 40(11): 1037-1045.
  • 9Cowell IG, Austin CA. Mechanism of generation of therapy related leukemia in responseto anti-topoisomeraseⅡ agents[J]. Int J Environ Res Public Health, 2012, 9(6): 2075-2091.
  • 10姜锦,吴敏媛,张瑞东.急性淋巴细胞白血病继发第二肿瘤5例[J].中国医刊,2008,43(11):61-62. 被引量:5

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部